Tianjin, China – September 28, 2022 – Genobio Pharmaceutical Co., Ltd, a wholly-owned subsidiary of Era Biology Group, which is a leader and pioneer of invasive fungal disease diagnostic field since 1997, has received Malaysia MDA Registration certification for its Full-Automatic Chemiluminescence Immunoassay System (FACIS-I). FACIS uses all-in-one mono-test design, fully automatic operation steps and intelligible and multi-functional software. It provides comprehensive solutions for invasive fungal disease diagnosis and more with the latest technology.
About Era Biology Group
Era Biology Group was established in 1997. It is a leader and pioneer of the invasive fungal disease diagnostic field. The headquarter is located in Tianjin, China. Until 2022, eight wholly-owned subsidiaries were established in Beijing, Tianjin, Suzhou, Guangzhou, Beihai, Shanghai and Canada. In China, Era Biology is the leading enterprise in the field of in vitro fungus diagnosis. Era Biology has been awarded the Marine Economic Innovation Development Demonstration Project by the National Oceanic Administration and Ministry of Finance. In 2017, Era Biology drafted the domestic industrial standard of “Fungus (1-3)-β-D-Glucan Test" together with the National Center for Clinical Laboratories. Globally, Era Biology has passed the authentication of CMD ISO 9001, ISO 13485, Korea GMP and MDSAP, and the products have certificates of CE, NMPA and FSC. Sticking to the slogan “Innovation for better health”, Era Biology insists on high quality and strict control while continuously conducting further research and development.
Full-Automatic Chemiluminescence Immunoassay System
The full-automatic chemiluminescence immunoassay system (FACIS-I) is a closed system, experiment whose methodology is chemiluminescence or photometry can be performed on this instrument for the rapid, early and accurate diagnosis.
Post time: Dec-02-2022